Role of Hypofractionated Radiotherapy With Concurrent Gemcitabine in Treatment of Urinary Bladder Carcinoma

Assiut University

Status: Unknown

Conditions: Urinary Bladder Cancer

Treatments: Radiation: Chemoradiation

Study type: Observational

Funder types: Other

Identifiers

NCT04812145

U.Bladder Cancer Radiotherapy

Details and patient eligibility

About

Estimate the response to modified hypofractionated radiotherapy concurrent with Gemcitabine in urinary bladder cancer patients .

Estimate local control, relapse free survival, overall survival and bladder preservation rate. Evaluate the toxicity of a modified hypofractionated chemoradiotherapy protocol for patients with invasive bladder cancer.

Enrollment: 50 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Pathologically confirmation of transitional cell carcinoma . Non metastatic invasive bladder cancer (TNM0) Any age group ≥ 18 years. Non pregnant female patients.

Exclusion criteria

• Other pathology than Transitional cell carcinoma Metastatic Patient Age less than 18 years